Studies of drug resistance and the dynamic behavior of HIV-1 protease through molecular dynamics simulations

Fangyu Ding; Carlos Simmerling

doi:10.1017/CBO9780511730412.008

6 - Studies of drug resistance and the dynamic behavior of HIV-1 protease through molecular dynamics simulations

from PART II - COMPUTATIONAL CHEMISTRY METHODOLOGY

Published online by Cambridge University Press: 06 July 2010

Fangyu Ding and

Carlos Simmerling

Edited by

Kenneth M. Merz, Jr ,

Dagmar Ringe and

Charles H. Reynolds

Show author details

Kenneth M. Merz, Jr: Affiliation:
University of Florida
Dagmar Ringe: Affiliation:
Brandeis University, Massachusetts
Charles H. Reynolds: Affiliation:
Johnson & Johnson Pharmaceutical Research & Development

Book contents

Get access

Summary

INTRODUCTION

The human immunodeficiency virus (HIV) was first discovered to be the causative agent of acquired immunodeficiency syndrome (AIDS) in the early 1980s. There are currently three main avenues for preventing virus replication. The first is to block attachment of virus to the host cell surface by inhibitors of binding to coreceptors, such as CCR5. The second is to block the process of reverse transcription, an approach taken by a major class of anti-AIDS drugs, including, for example, azidothymidine (AZT), delavirdine, nevirapin, and so on. The third way is to disrupt the function of the viral protease (HIV-PR) that cleaves the gag-pol polyproteins required to assemble an active virus by binding an inhibitor to the center of the protease and freezing it closed; this is described in more detail in this review. At present there are eleven FDA-approved protease inhibitors in clinical use: Agenerase (amprenavir), Aptivus (tipranavir), Crixivan (indinavir), Fortovase (saquinavir soft gel), Invirase (saquinavir hard gel), Kaletra (lopinavir-ritronavir), Lexiva (Fosamprenavir), Norvir (ritonavir), Prezista (darunavir), Reyataz (atazanavir), and Viracept. All these inhibitors can lose most of their potency when confronted with mutations associated with drug resistance. Therefore, a thorough understanding of the mechanistic events associated with binding of HIV-PR substrates and inhibitors is pharmacologically critical for the design of novel inhibitors of the enzyme. There is evidence that flexibility of the enzyme plays an important role in inhibitor binding and resistance.

Type: Chapter
Information: Drug Design
Structure- and Ligand-Based Approaches
, pp. 87 - 97

DOI: https://doi.org/10.1017/CBO9780511730412.008 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barresinoussi, F.; et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune-deficiency syndrome (AIDS). Science 1983, 220(4599), 868–871.Google Scholar

Gallo, R. C.; et al. Isolation of human T-cell leukemia-virus in acquired immune-deficiency syndrome (AIDS). Science 1983, 220(4599), 865–867.Google Scholar

Blair, W. S.; et al. HIV-1 entry – an expanding portal for drug discovery. Drug Discov. Today 2000, 5(5), p. 183–194.Google Scholar

Moore, J. P.; Stevenson, M.New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 2000, 1(1), 40–49.Google Scholar

Ren, J. S.; et al. High-resolution structures of HIV-1 RT from 4 RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2(4), 293–302.Google Scholar

Rhee, S. Y.; et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31(1), 298–303.Google Scholar

Condra, J. H.; et al. In-vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374(6522), 569–571.Google Scholar

Teague, S. J.Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2003, 2(7), 527–541.Google Scholar

McCammon, J. A.Target flexibility in molecular recognition. Biochim. Biophys. Acta 2005, 1754(1–2), 221–224.Google Scholar

Vondrasek, J.; Wlodawer, A.HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins 2002, 49(4), 429–431.Google Scholar

Navia, M. A.; et al. 3-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337(6208), 615–620.Google Scholar

Wlodawer, A.; et al. Conserved folding in retroviral proteases – crystal-structure of a synthetic HIV-1 protease. Science 1989, 245(4918), 616–621.Google Scholar

Lapatto, R.; et al. X-ray-analysis of HIV-1 proteinase at 2.7 a resolution confirms structural homology among retroviral enzymes. Nature 1989, 342(6247), 299–302.Google Scholar

Prabu-Jeyabalan, M.; et al. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol. 2006, 80(7), 3607–3616.Google Scholar

Heaslet, H.; et al. Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr. D Biol. Crystallogr. 2007, 63(Pt 8), 866–875.Google Scholar

Collins, J. R.; Burt, S. K.; Erickson, J. W.Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics. Nat. Struct. Mol. Biol. 1995, 2(4), 334–338.Google Scholar

Heaslet, H.; et al. Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr. D Biol. Crystallogr. 2007, 866–875.Google Scholar

Spinelli, S.; et al. The 3-dimensional structure of the aspartyl protease from the HIV-1 isolate Bru. Biochimie 1991, 73(11), 1391–1396.Google Scholar

Liu, F. L.; et al. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J. Mol. Biol. 2006, 358(5), 1191–1199.Google Scholar

Martin, P.; et al. “Wide-open” 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 2005, 13(12), 1887–1895.Google Scholar

Logsdon, B. C.; et al. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 2004, 78(6), 3123–3132.Google Scholar

Panchal, S. C.; et al. HIV-1 protease tethered heterodimer-pepstatin-A complex: NMR characterization. Curr. Sci. 2000, 79(12), 1684–1695.Google Scholar

LangeSavage, G.; et al. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms – structure/function relationship and influence of crystal packing. Eur. J. Biochem. 1997, 248(2), 313–322.Google Scholar

Miller, M.; et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3-a resolution. Science 1989, 246(4934), 1149–1152.Google Scholar

Wlodawer, A.; Vondrasek, J.Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249–284.Google Scholar

Hornak, V.; et al. HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(4), 915–920.Google Scholar

Ding, F.; Layten, M.; Simmerling, C.Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments. J. Am. Chem. Soc. 2008, 130 (23), 7184–7185.Google Scholar

Layten, M.; Hornak, V.; Simmerling, C.The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts. J. Am. Chem. Soc. 2006, 128(41), 13360–13361.Google Scholar

Nicholson, L. K.; et al. Flexibility and function in HIV-1 protease. Nat. Struct. Biol. 1995, 2(4), 274–280.Google Scholar

Freedberg, D. I.; et al. Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci. 2002, 11(2), 221–232.Google Scholar

Ishima, R.; Louis, J. M.A diverse view of protein dynamics from NMR studies of HIV-1 protease flaps. Proteins 2007, 70, 1408–1415.Google Scholar

Galiano, L.; Bonora, M.; Fanucci, G. E.Interflap distances in HIV-1 protease determined by pulsed EPR measurements. J. Am. Chem. Soc. 2007, 129(36), 11004–11005.Google Scholar

Ishima, R.; et al. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 1999, 7(9), 1047–1055.Google Scholar

Katoh, E.; et al. A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex. Protein Sci. 2003, 12(7), 1376–1385.Google Scholar

Collins, J. R.; Burt, S. K.; Erickson, J. W.Flap opening in HIV-1 protease simulated by activated molecular dynamics. Nat. Struct. Biol. 1995, 2(4), 334–338.Google Scholar

Scott, W. R. P.; Schiffer, C. A.Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 2000, 8(12), 1259–1265.Google Scholar

Meagher, K. L.; Carlson, H. A.Solvation influences flap collapse in HIV-1 protease. Proteins 2005, 58(1), 119–125.Google Scholar

Hamelberg, D.; McCammon, J. A.Fast peptidyl cis-trans isomerization within the flexible Gly-Rich flaps of HIV-1 protease. J. Am. Chem. Soc. 2005, 127 (40), 13778–13779.Google Scholar

Perryman, A. L.; Lin, J. H.; McCammon, J. A.HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13(4), 1108–1123.Google Scholar

Perryman, A. L.; Lin, J. H.; McCammon, J. A.Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design. Biopolymers 2006, 82(3), 272–284.Google Scholar

Perryman, A. L.; Lin, J. H.; McCammon, J. A.Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design. Chem. Biol. Drug Des. 2006, 67(5), 336–345.Google Scholar

Chang, C. E.; et al. Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model. Biophys. J. 2006, 90(11), 3880–3885.Google Scholar

Tozzini, V.; McCammon, J. A.A coarse grained model for the dynamics of flap opening in HIV-1 protease. Chem. Phys. Lett. 2005, 413(1–3), 123–128.Google Scholar

Hornak, V.; et al. HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(4), 915–920.Google Scholar

Pitera, J. W.; Swope, W.Understanding folding and design: Replica-exchange simulations of “Trp-cage” miniproteins. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(13), 7587–7592.Google Scholar

Zhou, R.Free energy landscape of protein folding in water: explicit vs. implicit solvent. Proteins 2003, 53(2), 148–161.Google Scholar

Zhou, R.; Berne, B. J.Can a continuum solvent model reproduce the free energy landscape of a β-hairpin folding in water?Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12777–12782.Google Scholar

Roe, D. R.; et al. Secondary structure bias in generalized born solvent models: Comparison of conformational ensembles and free energy of solvent polarization from explicit and implicit solvation. J. Phys. Chem. B 2007, 111(7), 1846–1857.Google Scholar

Geney, R.; et al. Investigation of salt bridge stability in a generalized born solvent model. J. Chem. Theor. Comput. 2006, 2(1), 115–127.Google Scholar

Damm, K. L.; Ung, P. M.; Quintero, J. J.; Gestwicki, J. E.; Carlson, H. A.A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 2008, 89, 643–652.Google Scholar

Hornak, V.; et al. HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state. J. Am. Chem. Soc. 2006, 128(9), 2812–2813.Google Scholar

Krausslich, H. G.Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(8), 3213–3217.Google Scholar

Sayer, J. M.; Liu, F.; Ishima, R.; Weber, I. T.; Louis, J. M.Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J. Biol. Chem. 2008, 283(19), 13459–13470.Google Scholar

Perryman, A. L.; Lin, J.-H.; McCammon, J. A.HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13(4), 1108–1123.Google Scholar

Tyndall, J. D. A.; et al. Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease: implications for the catalytic mechanism. Biochemistry 2008, 47(12), 3736–3744.Google Scholar

Toth, G.; Borics, A.Flap opening mechanism of HIV-1 protease. J. Mol. Graph. Model. 2006, 24(6), 465–474.Google Scholar

Toth, G.; Borics, A.Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases. Biochemistry 2006, 45(21), 6606–6614.Google Scholar

Spinelli, S.; et al. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 1991, 73(11), 1391–1396.Google Scholar

Lapatto, R.; et al. X-ray analysis of HIV-1 proteinase at 2.7 [angst] resolution confirms structural homology among retroviral enzymes. Nature 1989, 342(6247), 299–302.Google Scholar

Marqusee, S.; Robbins, V. H.; Baldwin, R. L.Unusually stable helix formation in short alanine-based peptides. Proc. Natl. Acad. Sci. U.S.A. 1989, 86(14), 5286–5290.Google Scholar

Kovalskyy, Dmytro, Dubyna, V.; Mark, A. E.; Kornelyuk, A.A molecular dynamics study of the structural stability of HIV-1 protease under physiological conditions: the role of Na+ ions in stabilizing the active site. Proteins 2005, 58(2), 450–458.Google Scholar

Eisenmesser, E. Z.; Bosco, D. A.; Akke, M.; Kern, D.Enzyme dynamics during catalysis. Science 2002, 295(5559), 1520–1523.Google Scholar

Huang, Y. J.; Montelione, G. T.Structural biology: proteins flex to function. Nature 2005, 438(7064), 36–37.Google Scholar

Lange, O. F.; Lakomek, N.-A.; Farès, C.; Schröder, G. F.; Walter, K. F. A.; Becker, S.; Meiler, J.; Grubmüller, H.; Griesinger, C.; Groot, B. L.Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Protein, 2008, 320(5882) 1471–1475.Google Scholar

Kohl, N. E.; et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85(13), 4686–4690.Google Scholar

O'Loughlin, T. L.; Greene, D. N.; Matsumura, I.Diversification and specialization of HIV protease function during in vitro evolution. Mol. Biol. Evol. 2006, 23(4), 764–772.Google Scholar

Piana, S.; Carloni, P.; Rothlisberger, U.Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci. 2002, 11(10), 2393–2402.Google Scholar

Piana, S.; Carloni, P.; Parrinello, M.Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J. Mol. Biol. 2002, 319(2) 567–583.Google Scholar

Wang, W.; Kollman, P. A.Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(26), 14937–14942.Google Scholar

Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A.Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002; 10(3), 369–381.Google Scholar

Foulkes-Murzycki, J. E.; Scott, W. R. P.; Schiffer, C. A.Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 2007, 15(2), 225–233.Google Scholar

Luque, I.; et al. Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Biochemistry 1998, 37(17), 5791–5797.Google Scholar

Vega, S.; et al. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins 2004, 55(3), 594–602.Google Scholar

Rick, S. W.; Erickson, J. W.; Burt, S. K.Reaction path and free energy calculations of the transition between alternate conformations of HIV-1 protease. Proteins 1998, 32(1), 7–16.Google Scholar

Todd, M. J.; et al. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 2000, 39(39) 11876–11883.Google Scholar

Ohtaka, H.; et al. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int. J. Biochem. Cell Biol. 2004, 36(9), 1787–1799.Google Scholar

Yoshimura, K.; et al., JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(15), 8675–8680.Google Scholar

Velazquez-Campoy, A.; Freire, E.Incorporating target heterogeneity in drug design. J. Cell. Biochem. 2001, 37, 82–88.Google Scholar

Velazquez-Campoy, A.; Kiso, Y.; Freire, E.The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 2001, 390(2), 169–175.Google Scholar

Ghosh, A. K.; et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem. 2006, 49(17), 5252–5261.Google Scholar

Tie, Y. F.; et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 2004, 338(2), 341–352.Google Scholar

Martin, P.; et al. “Wide-open” 1.3 angstrom structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 2005, 13(12), 1887–1895.Google Scholar

Pillai, B.; Kannan, K. K.; Hosur, M. V.1.9 angstrom X-ray study shows closed flap conformation in crystals of tethered HIV-1PR. Proteins 2001, 43(1), 57–64.Google Scholar

Hwang, Y. S.; Chmielewski, J.Development of low molecular weight HIV-1 protease dimerization inhibitors. J. Med. Chem. 2005, 48(6), 2239–2242.Google Scholar

Shultz, M. D.; et al. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach. J. Am. Chem. Soc. 2004, 126(32), 9886–9887.Google Scholar

Bowman, M. J.; Byrne, S.; Chmielewski, J.Switching between allosteric and dimerization inhibition of HIV-1 protease. Chem. Biol. 2005, 12(4), 439–444.Google Scholar

Rezacova, P.; et al. Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide. J. Struct. Biol. 2005, 149(3), 332–337.Google Scholar

Sperka, T.; et al. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 2005, 15(12), 3086–3090.Google Scholar

Gunasekaran, K.; Ma, B. Y.; Nussinov, R.Is allostery an intrinsic property of all dynamic proteins?Proteins 2004, 57(3), 433–443.Google Scholar

Fleisher, D.; Bong, R.; Stewart, B. H.Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 1996, 19(2), 115–130.Google Scholar

Sohma, Y.; et al. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. J. Med. Chem. 2003, 46(19), 4124–4135.Google Scholar

Book contents

6 - Studies of drug resistance and the dynamic behavior of HIV-1 protease through molecular dynamics simulations

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive